These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 36504557)

  • 1. Glucagon-like peptide-2 analogues for Crohn's disease patients with short bowel syndrome and intestinal failure.
    Pizzoferrato M; Puca P; Ennas S; Cammarota G; Guidi L
    World J Gastroenterol; 2022 Nov; 28(44):6258-6270. PubMed ID: 36504557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.
    Hargrove DM; Alagarsamy S; Croston G; Laporte R; Qi S; Srinivasan K; Sueiras-Diaz J; Wiśniewski K; Hartwig J; Lu M; Posch AP; Wiśniewska H; Schteingart CD; Rivière PJ; Dimitriadou V
    J Pharmacol Exp Ther; 2020 May; 373(2):193-203. PubMed ID: 32075870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.
    Yazbeck R
    Curr Opin Mol Ther; 2010 Dec; 12(6):798-809. PubMed ID: 21154171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An updated overview of glucagon-like peptide-2 analog trophic therapy for short bowel syndrome in adults.
    Zhu C; Li Y
    J Int Med Res; 2022 Mar; 50(3):3000605221086145. PubMed ID: 35343263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-2 analog Teduglutide in active Crohn's disease and short bowel syndrome: Confirmation of anti-inflammatory role and future perspectives.
    Borghini R; Caronna R; Donato G; Picarelli A
    Dig Liver Dis; 2020 Jun; 52(6):686-687. PubMed ID: 32340888
    [No Abstract]   [Full Text] [Related]  

  • 6. Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo-controlled, randomized phase 2 trial.
    Eliasson J; Hvistendahl MK; Freund N; Bolognani F; Meyer C; Jeppesen PB
    JPEN J Parenter Enteral Nutr; 2022 May; 46(4):896-904. PubMed ID: 34287970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term clinical evaluation of teduglutide for patients with Crohn's disease on home parenteral support for postoperative short bowel syndrome with intestinal failure.
    Sato T; Uchino M; Takeuchi J; Fujihira Y; Shimizu K; Yokoyama K; Yagi S; Kaku K; Takashima Y; Ikenouchi M; Kojima K; Kawai M; Nagase K; Kamikozuru K; Yokoyama Y; Takagawa T; Ikeuchi H; Watanabe K; Shinzaki S
    Clin Nutr; 2023 May; 42(5):722-731. PubMed ID: 37001195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intestinal iatrogenic hyperadaptation in patients with short bowel syndrome and Crohn's disease: Is this an indication for mandatory lifelong injections of teduglutide?
    Mazzuoli S; Regano N; Lamacchia S; Silvestri A; Guglielmi FW
    Nutrition; 2021; 91-92():111396. PubMed ID: 34399400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The indications and results of the use of teduglutide in patients with short bowel.
    El Khatib M; Billiauws L; Joly F
    Curr Opin Clin Nutr Metab Care; 2023 Sep; 26(5):449-454. PubMed ID: 37421385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Potential of GLP-2 Analogs in Gastrointestinal Disorders: Current Knowledge, Nutritional Aspects, and Future Perspectives.
    Kounatidis D; Vallianou NG; Tsilingiris D; Christodoulatos GS; Geladari E; Stratigou T; Karampela I; Dalamaga M
    Curr Nutr Rep; 2022 Dec; 11(4):618-642. PubMed ID: 35933503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of glucagon-like peptide 2 in patients with short bowel syndrome: a systematic review and network meta-analysis.
    Sabra HK; Remeih GS; Kereet IM; Hamad M; Ahmed YA; Jahangir K; Bakr MA; Alagelli FA; Sherif H; Elsaid M
    J Gastrointest Surg; 2024 Jul; 28(7):1194-1205. PubMed ID: 38663565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.
    Jeppesen PB; Pertkiewicz M; Forbes A; Pironi L; Gabe SM; Joly F; Messing B; Loth S; Youssef NN; Heinze H; Berghöfer P
    Clin Nutr; 2013 Oct; 32(5):713-21. PubMed ID: 23587733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the Intestinotrophic Effects of 2 Glucagon-Like Peptide-2 Analogues in the Treatment of Short-Bowel Syndrome in Neonatal Piglets.
    Pauline ML; Nation PN; Wizzard PR; Hinchliffe T; Wu T; Dimitriadou V; Turner JM; Wales PW
    JPEN J Parenter Enteral Nutr; 2021 Mar; 45(3):538-545. PubMed ID: 32437048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal adaptation and rehabilitation in adults with short bowel syndrome.
    Pironi L
    Curr Opin Clin Nutr Metab Care; 2024 Sep; 27(5):457-461. PubMed ID: 38963563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of short bowel syndrome: Breaking the therapeutic ceiling?
    Wauters L; Joly F
    Nutr Clin Pract; 2023 May; 38 Suppl 1():S76-S87. PubMed ID: 37115030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-Bowel Adaptation: A Case of Morphological Changes Induced by Teduglutide in Short-Bowel Syndrome With Intestinal Failure.
    Mouillot T; Boehm V; Treton X; Ferrandi E; Kapel N; Cazals-Hatem D; Joly F
    JPEN J Parenter Enteral Nutr; 2020 Jul; 44(5):940-943. PubMed ID: 32187383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.
    Kochar B; Long MD; Shelton E; Young L; Farraye FA; Yajnik V; Herfarth H
    J Clin Gastroenterol; 2017 Jul; 51(6):508-511. PubMed ID: 27433811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for the treatment of short bowel syndrome.
    Frau T; El Khatib M; De Dreuille B; Billiauws L; Nuzzo A; Joly F
    Expert Opin Emerg Drugs; 2024 Sep; 29(3):277-288. PubMed ID: 38761162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apraglutide, a novel once-weekly glucagon-like peptide-2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: An open-label phase 1 and 2 metabolic balance trial.
    Eliasson J; Hvistendahl MK; Freund N; Bolognani F; Meyer C; Jeppesen PB
    JPEN J Parenter Enteral Nutr; 2022 Sep; 46(7):1639-1649. PubMed ID: 35233802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of teduglutide in adults with short bowel syndrome-associated intestinal failure.
    Pironi L; Allard JP; Joly F; Geransar P; Genestin E; Pape UF
    Nutr Clin Pract; 2024 Feb; 39(1):141-153. PubMed ID: 37294295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.